We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

84 hedge funds and large institutions have $527M invested in UroGen Pharma in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more call options, than puts

Call options by funds: $1.44M | Put options by funds: $553K

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

14% more funds holding

Funds holding: 74 → 84 (+10)

6% more capital invested

Capital invested by funds: $497M → $527M (+$30M)

4.88% more ownership

Funds ownership: 65.73% → 70.62% (+4.9%)

Holders
84
Holders Change
+10
Holders Change %
+13.51%
% of All Funds
1.82%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
25
Increased
27
Reduced
19
Closed
14
Calls
$1.44M
Puts
$553K
Net Calls
+$888K
Net Calls Change
-$47K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$33.8M
2
State Street
State Street
Massachusetts
+$10.6M
3
PM
Prosight Management
Texas
+$3.8M
4
DG
Delek Group
Israel
+$3.51M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.26M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$12M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.6M
3
Man Group
Man Group
United Kingdom
-$5.99M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.5M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$2.07M -$7.6M -206,087 -78%
Northern Trust
27
Northern Trust
Illinois
$1.99M +$1.07M +29,142 +111%
USAA
28
United Services Automobile Association
Texas
$1.82M +$17.3K +470 +0.9%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$1.67M +$1.27M +34,446 +290%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.6M +$1.64M +44,448 New
AA
31
ALPS Advisors
Colorado
$1.56M -$157K -4,271 -9%
N
32
Nuveen
North Carolina
$1.54M +$1.58M +42,826 New
PFO
33
Pathstone Family Office
New Jersey
$1.47M +$1.51M +40,950 New
Charles Schwab
34
Charles Schwab
California
$1.4M +$1.44M +38,977 New
Swiss National Bank
35
Swiss National Bank
Switzerland
$1.16M – – –
BHB
36
Bank Hapoalim BM
Israel
$933K +$68K +1,845 +8%
AS
37
Altshuler Shaham
Israel
$931K +$44K +1,194 +5%
AllianceBernstein
38
AllianceBernstein
Tennessee
$787K +$807K +21,900 New
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$758K +$777K +21,079 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$690K +$708K +19,200 New
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$645K +$217K +5,881 +49%
CBA
42
Coastal Bridge Advisors
Connecticut
$636K +$284K +7,692 +77%
Man Group
43
Man Group
United Kingdom
$592K -$5.99M -162,512 -91%
EMG
44
ETF Managers Group
New Jersey
$583K +$221K +5,985 +51%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$543K +$47.9K +1,300 +9%
DCM
46
DAFNA Capital Management
California
$539K – – –
AIM
47
ARK Investment Management
Florida
$486K +$167K +4,522 +50%
Barclays
48
Barclays
United Kingdom
$436K -$680K -18,437 -60%
AIG
49
American International Group
New York
$428K +$439K +11,913 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$417K +$428K +11,602 New
1
2
3 4

URGN Hedge Fund Activity: Q2 2019 in Review

84 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2019, worth a combined $527M — up 6% from $497M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new URGN positions and 14 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $33.8M. The largest seller was Consonance Capital Management, cutting an estimated $12M.

  • 84 institutional investors held UroGen Pharma (URGN) as of Q2 2019, up from 74 in Q1 2019.
  • Funds reported $527M of UroGen Pharma stock for Q2 2019, up 6% quarter-over-quarter.
  • 25 funds opened new UroGen Pharma positions in Q2 2019 and 14 closed out, a net change of +11 holders.
  • The largest UroGen Pharma buyer in Q2 2019 was BlackRock, an estimated $33.8M added.
  • The largest UroGen Pharma seller in Q2 2019 was Consonance Capital Management, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2019.